波浪生命科学

US · WVE #3515 按市值排名上市于 2015

3.13 -0.06 -1.88%

实时 - 追踪5344个代码 - 心跳于12秒前 · 2026-10-16 19:30

✦ 量化股权信号计算方式说明

减持

最近一期（2026/Q3）披露持股的机构数量减少了2家。
机构持股总比例下降了3.1个百分点。

机构持股

机构持股比例: 99.87% -3.13pp
机构数量: 287 -2
数据截至: 2026/Q3 较上一报告期

持股变动 vs 资金流向

方向分歧

机构在上一报告期减持了股份，同时该股在最近20个交易日的主力资金呈净流入——两者方向出现分歧。

机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。

持股人类型

Mutual Fund40.04%

Hedge Fund25.90%

VC/PE Fund24.38%

Public Company7.60%

Private Company1.32%

Individual/Insider0.41%

Government Pension Fund0.25%

Insurance Company0.23%

Family Office/Trust0.13%

主要股东截至 2026-08-11

RA Capital Management, L.P. 13.69% · 26.98M 股

BlackRock 9.75% · 19.20M 股

GSK Equity Investments, Limited 9.26% · 18.25M 股

Maverick Capital, Ltd. 5.22% · 10.28M 股

Shin Nippon Biomedical Laboratories, Ltd. 4.88% · 9.61M 股

Driehaus Capital Management LLC 2.76% · 5.44M 股

PRIMECAP Management Company 2.72% · 5.35M 股

683 Capital Management, LLC 2.51% · 4.95M 股

FMR 2.50% · 4.92M 股

State Street Global Advisors 2.46% · 4.84M 股

条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。

内部人持股

共追踪50份申报 · 18次买入 · 27次卖出

姓名	职务	持股比例
RA Capital Management, L.P.	--	13.69%
Chandra Vargeese	CTO & Head of Platform Discovery Sciences	0.17%
Gregory L. Verdine	Director	0.13%
Kyle B. Moran	Chief Financial Officer	0.03%
Heidi L. Wagner	Independent Director	0.02%
Peter Kolchinsky	Independent Director	0.01%
Aik Na Tan	Independent Director	0.01%
Ken Takanashi	Independent Director	0.01%
Paul B. Bolno	Chief Executive Officer	0.01%
Erik Ingelsson	Chief Scientific Officer	0.01%

内部人交易最近的 Form 4 申报记录

日期	姓名	职务	类型	股数	价格
2026-08-11	Adrian George Rawcliffe	Independent Director	Automatic Disposition	-12,700	$5.29
2026-08-10	Ken Takanashi	Independent Director	Automatic Disposition	-3,864	$6.01
2026-08-10	Heidi L. Wagner	Independent Director	Derivative Exercise and Sale	-7,000	$5.97–6.01
2026-08-10	Aik Na Tan	Independent Director	Automatic Disposition	-432	$6.01
2026-04-08	Christopher I. Wright	Chief Medical Officer	Initial Statement of Beneficial	0	--
2026-04-08	Erik Ingelsson	Chief Scientific Officer	Initial Statement of Beneficial	0	--
2026-03-29	RA Capital Management, L.P.	--	Open Market Acquisition	+8,772,496	$6.06–6.50
2026-03-22	Shin Nippon Biomedical Laboratories, Ltd.	--	Derivative Exercise and Retained	+3,901,348	--
2026-02-25	Christopher Francis	Senior VP of Corporate Development & Head of Emerging Areas	Derivative Exercise and Sale	-33,194	$3.87–15.09
2026-02-08	Chandra Vargeese	CTO & Head of Platform Discovery Sciences	Open Market Disposition	-3,228	$13.45
2026-02-08	Kyle B. Moran	Chief Financial Officer	Open Market Disposition	-3,588	$13.45
2026-02-08	Paul B. Bolno	Chief Executive Officer	Open Market Disposition	-10,480	$13.45
2026-02-08	Christopher Francis	Senior VP of Corporate Development & Head of Emerging Areas	Open Market Disposition	-1,883	$13.45
2026-02-04	Chandra Vargeese	CTO & Head of Platform Discovery Sciences	Other Acquisition	+45,625	--
2026-02-04	Chandra Vargeese	CTO & Head of Platform Discovery Sciences	Other Derivative Acquisition	+273,750	$12.75
2026-02-04	Kyle B. Moran	Chief Financial Officer	Other Acquisition	+45,625	--
2026-02-04	Kyle B. Moran	Chief Financial Officer	Other Derivative Acquisition	+273,750	$12.75
2026-02-04	Paul B. Bolno	Chief Executive Officer	Other Acquisition	+165,000	--
2026-02-04	Paul B. Bolno	Chief Executive Officer	Other Derivative Acquisition	+1,000,000	$12.75
2026-02-04	Christopher Francis	Senior VP of Corporate Development & Head of Emerging Areas	Other Acquisition	+38,750	--

Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。

报价时间 2026-10-16 19:30:05 · 仅供参考，不构成投资建议，也未考虑您的具体情况。